Verve Therapeutics, Inc. (VERV) Financials

VERV Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 752.7 million 153.2 million
2023-09-30 612.4 million 152.0 million
2023-06-30 589.1 million 123.9 million
2023-03-31 634.4 million 124.9 million

VERV Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -42.9 million 9.3 million
2023-09-30 -12.9 million 8.8 million
2023-06-30 -50.6 million 9.0 million
2023-03-31 -52.5 million 8.0 million

VERV Net Income

No data available :(

VERV Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 624.0 million - 74.9 million
2023-09-30 485.2 million - 76.8 million
2023-06-30 462.5 million - 77.9 million
2023-03-31 508.7 million - 80.1 million

VERV Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 69.7 million
2023-09-30 63.2 million
2023-06-30 62.0 million
2023-03-31 61.8 million

VERV Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 2.2 million 46.8 million 12.3 million -
2023-09-30 1.1 million 43.8 million 11.7 million -
2023-06-30 2.7 million 47.3 million 13.4 million -
2023-03-31 3.4 million 47.1 million 12.6 million -

VERV Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 5.1 million 1.5 million
2023-09-30 3.1 million 3.2 million
2023-06-30 2.1 million 3.0 million
2023-03-31 1.4 million 2.8 million

VERV

Price: $6

52 week price:
6.00
21.42

Earnings Per Share: -3.12 USD

P/E Ratio: -4.03

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 434163

Market Capitalization: 731.7 million

Links: